Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009738 | 1.00 | TAAR1 (0.52) | TAAR1F2TMPRSS4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL525033 | 0.98 | TAAR1 (0.50) | TAAR1F2TMPRSS4TP53CYP1A2 | |
| SCHEMBL6680949 | 0.83 | TAAR1 (0.50) | TAAR1HTR2ASLC6A2HTR6HRH1 | |
| SCHEMBL5149827 | 0.83 | ELANE (0.44) | TAAR1F2TMPRSS4TP53CYP1A2 | |
| SCHEMBL731097 | 0.82 | TAAR1 (0.52) | TAAR1CYP1A2CYP2D6HTR2ASLC6A2 | |
| SCHEMBL8337031 | 0.80 | TAAR1 (0.50) | TAAR1CYP1A2CYP2D6HTR2ASLC6A2 | |
| SCHEMBL1805940 | 0.80 | TAAR1 (0.50) | TAAR1CYP1A2HTR2ASLC6A2HTR6 | |
| Hydrochloric Acid SCHEMBL14157101 | 0.78 | TAAR1 (0.48) | TAAR1F2TMPRSS4CYP1A2CYP2D6 | |
| SCHEMBL4598969 | 0.78 | TAAR1 (0.48) | TAAR1HTR2ASLC6A2HTR6HRH1 | |
| SCHEMBL39171 | 0.78 | TAAR1 (0.45) | TAAR1F2HTR2ASLC6A2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565905-B1 | Mass spectrometry assay for plasma-renin | QUEST DIAGNOSTICS INVEST INC (US) | 2015-12-30 | — | — | EP | claimed |
| WO-2013136277-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CARDIOVASCULAR DISEASES | UNIMARK REMEDIES LTD. (IN) | 2013-09-19 | — | — | WO | claimed |
| EP-1858540-A2 | STABILIZED COMPOSITIONS CONTAINING NATRIURETIC PEPTIDES | Bio-Rad Laboratories, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| WO-2006088624-A2 | STABILIZED COMPOSITIONS CONTAINING NATRIURETIC PEPTIDES | BIO-RAD LABORATORIES, INC. (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060183681-A1 | Stabilized compositions containing natriuretic peptides | BIO-RAD LABORATORIES, INC. (US) | 2006-08-17 | — | — | US | claimed |
| EP-1421175-A4 | POLYMER STABILIZED PROTEINASES | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1421175-A2 | POLYMER STABILIZED PROTEINASES | Mountain View Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030012777-A1 | Polymer conjugates of proteinases | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2003002716-A2 | POLYMER STABILIZED PROTEINASES | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| US-12508311-B2 | Fusion protein, and preparation method and use thereof | SUN YAT-SEN UNIVERSITY (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12378543-B2 | Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles | STRECK LLC (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4427588-A2 | COMPOSITIONS FOR HEMOLYSIS AND COAGULATION REGULATION AND STABILIZATION OF EXTRACELLULAR VESICLES | Streck LLC (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3697209-B1 | COMPOSITIONS FOR HEMOLYSIS AND COAGULATION REGULATION AND STABILIZATION OF EXTRACELLULAR VESICLES | STRECK LLC (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-115119829-B | Compositions for the modulation of haemolysis and coagulation of extracellular vesicles and stabilization | 斯特雷克股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-1997038013-A1 | MODULATION OF MAMMALIAN TELOMERASE BY PEPTIDE NUCLEIC ACIDS | THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997015687-A1 | TELOMERASE ACTIVITY ASSAYS | GERON CORPORATION (US) | 1997-05-01 | — | — | WO | disclosed |
| EP-0759074-A1 | STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES | DADE INTERNATIONAL INC. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1997002836-A1 | CLOSTRIDIUM DIFFICILE TOXINS AS MUCOSAL ADJUVANTS | ORAVAX, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1996040885-A2 | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION | ATHENA NEUROSCIENCES, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996027661-A1 | STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES | DADE INTERNATIONAL INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508311-B2 | Fusion protein, and preparation method and use thereof | KRAS, LAMP2, NRAS | TAAR1 4717/4885F2 3039/4885TMPRSS4 585/4885 |
| US-20030012777-A1 | Polymer conjugates of proteinases | PRNP, PRSS3, PRSS1 | TAAR1 4494/4885F2 1131/4885TMPRSS4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.